Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Early Detection of Cancer and Its Recurrence – Technologies and...
share announcement

Early Detection of Cancer and Its Recurrence – Technologies and Biomarkers to Enhance Clinical Translation

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 5074

Special Issue Editor

Dr. Rajan P. Kulkarni

E-Mail Website
Guest Editor
Department of Dermatology, Oregon Health & Science University, Portland, OR 97239, USA
Interests: cancer recurrence; treatment response; immunotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Early detection of cancer and earlier detection of its recurrence is of paramount importance to improve overall outcomes. Here we are interested not only in the biology and biomarkers related to earlier detection (including both circulating and tumor-specific markers) but also in advancing technologies to assist with translating these findings to clinical settings. In addition, many novel ideas fail to have clinical uptake for various reasons including due to cost, time, or complex workflows that are difficult to implement in a clinical setting. Articles of interest will thus span from technological improvements and advancements that may make the translational process to clinical applicability faster, easier, and/or less costly to specific markers or panels of markers that help to predict the presence of cancer or signify a change in the tumor behavior. In addition, articles that deal with prediction of treatment resistance (either prior to starting initial treatment or while on treatment) are also welcome, with emphasis on immunotherapies. Of special interest are findings that have applicability towards several cancers (multi-cancer or pan-cancer), though studies that are focused on single cancer types are also welcomed.

Dr. Rajan P. Kulkarni
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • early detection
  • biomarkers
  • methodologies
  • novel technology
  • cancer recurrence
  • treatment response
  • immunotherapy
  • treatment resistance
  • clinical translation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 1686 KiB  
Article
Intraoperative Flow Cytometry for the Rapid Diagnosis and Validation of Surgical Clearance of Non-Melanoma Skin Cancer: A Prospective Clinical Feasibility Study
by Georgios Markopoulos, Evangeli Lampri, Ioulia Tragani, Nikolaos Kourkoumelis, Georgios Vartholomatos and Konstantinos Seretis
Cancers 2024, 16(4), 682; https://doi.org/10.3390/cancers16040682 - 6 Feb 2024
Cited by 1 | Viewed by 1283
Abstract
Non-melanoma skin cancer (NMSC) is the most prevalent cancer in humans, with a high global incidence. We present a prospective clinical feasibility study on the use of intraoperative flow cytometry (iFC) for the instant diagnosis of NMSC and its complete surgical clearance. Flow [...] Read more.
Non-melanoma skin cancer (NMSC) is the most prevalent cancer in humans, with a high global incidence. We present a prospective clinical feasibility study on the use of intraoperative flow cytometry (iFC) for the instant diagnosis of NMSC and its complete surgical clearance. Flow cytometry, a laser-based technique, quantifies cell features, which has applications in cancer research. This study aim is to explore the potential applicability of iFC in detecting and characterizing NMSC and its surgical margins. In total, 30 patients who underwent diagnosis for NMSC were recruited. The method demonstrated high sensitivity (95.2%) and specificity (87.1%), with an accuracy of 91.1%, as confirmed with a receiver operating characteristic curve analysis. The results also indicated that most tumors were diploid, with two cases being hypoploid. The average G0/G1 fractions for normal and tumor tissue samples were 96.03 ± 0.30% and 88.03 ± 1.29%, respectively, with the tumor index escalating from 3.89 ± 0.30% to 11.95 ± 1.29% in cancerous cells. These findings underscore iFC’s capability for precise intraoperative NMSC characterization and margin evaluation, promising enhanced complete tumor excision rates. Given the technique’s successful application in various other malignancies, its implementation in NMSC diagnosis and treatment holds significant promise and warrants further research in clinical trials. Full article
(This article belongs to the Special Issue Early Detection of Cancer and Its Recurrence – Technologies and Biomarkers to Enhance Clinical Translation)
►▼ Show Figures

Figure 1

19 pages, 3139 KiB  
Article
Single-Cell Identification of Melanoma Biomarkers in Circulating Tumor Cells
by Reilly Fankhauser, Matthew Chang, Zachary Garrison, Rachel Berryman, Olivia M. Lucero, Allison Fuiten, Nicholas DePatie, Hilary Seifert and Rajan P. Kulkarni
Cancers 2022, 14(19), 4921; https://doi.org/10.3390/cancers14194921 - 8 Oct 2022
Cited by 5 | Viewed by 3438
Abstract
The current standard for investigating tumors is surgical biopsy, which is costly, invasive, and difficult to perform serially. As an adjunct, circulating tumor cells (CTCs)—cells that have broken away from the primary tumor or metastatic sites—can be obtained from a blood draw and [...] Read more.
The current standard for investigating tumors is surgical biopsy, which is costly, invasive, and difficult to perform serially. As an adjunct, circulating tumor cells (CTCs)—cells that have broken away from the primary tumor or metastatic sites—can be obtained from a blood draw and offer the potential for obtaining serial genetic information and serving as biomarkers. Here, we detail the potential for melanoma CTCs to serve as biomarkers and discuss a clinically viable methodology for single-cell CTC isolation and analysis that overcomes previous limitations. We explore the use of melanoma CTC biomarkers by isolating and performing single-cell RNA sequencing on CTCs from melanoma patients. We then compared transcriptional profiles of single melanoma CTCs against A375 cells and peripheral blood mononuclear cells to identify unique genes differentially regulated in circulating melanoma tumor cells. The information that can be obtained via analysis of these CTCs has significant potential in disease tracking. Full article
(This article belongs to the Special Issue Early Detection of Cancer and Its Recurrence – Technologies and Biomarkers to Enhance Clinical Translation)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop